Ponoi Capital II, LP is Director & 10% Owner at NGM BIOPHARMACEUTICALS INC (NGM). They have made 8 open-market trades across 2 companies since 2019, most recently 2023-01-30.
CIK 0001732601
7 open-market purchases totalling $5.2M since 2019, against 1 sale. Across 7 scored buys the stock is up 15.0% at ninety days, and 7.8 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 43% | 57% | 71% |
| Avg Move | -0.1% | +2.9% | +15.0% |
| Alpha | -2.2% | +0.3% | +7.8% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NGM | BUY | 2023-01-30 | 2023-02-01 | $5.00 | $38K | -9.6% | -20.7% | -32.2% |
| NGM | BUY | 2022-10-27 | 2022-10-31 | $4.86 | $374K | +3.8% | +0.7% | -8.7% |
| NGM | BUY | 2022-10-25 | 2022-10-27 | $4.81 | $595K | +14.1% | +3.4% | +3.6% |
| NGM | BUY | 2022-05-16 | 2022-05-17 | $12.90 | $428K | +2.1% | -4.4% | +30.6% |
| RAPT | SELL | 2021-09-27 | 2021-09-29 | $34.53 | $578K | -5.5% | -3.1% | +11.8% |
| NGM | BUY | 2020-03-23 | 2020-03-25 | $11.89 | $3.6M | -1.8% | +28.6% | +64.0% |
| NGM | BUY | 2019-10-22 | 2019-10-24 | $11.93 | $52K | -1.5% | +21.7% | +40.7% |
| NGM | BUY | 2019-06-24 | 2019-06-26 | $13.78 | $169K | -7.8% | -8.8% | +7.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.